US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

33.10

-0.2651-0.79%

Post-market: 33.120.0250+0.08%18:32 EST

Volume:57.29K

Turnover:1.90M

Market Cap:162.83M

PE:- -

High:33.73

Open:33.73

Low:33.02

Close:33.36

52wk High:34.00

52wk Low:25.63

Shares:4.92M

Float Shares:4.53M

Volume Ratio:0.40

T/O Rate:1.26%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns

Why Is Immunome Stock Soaring Monday?

Benzinga_recent_news

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":33.095,"timestamp":1766005200000,"preClose":33.3601,"halted":0,"volume":57293,"hourTrading":{"tag":"盘后","latestPrice":33.12,"preClose":33.095,"latestTime":"18:32 EST","volume":30,"amount":991.93,"timestamp":1766014373725},"delay":0,"floatShares":4530000,"shares":4920000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.2651,"latestTime":"12-17 16:00:00 EST","open":33.73,"high":33.73,"low":33.0229,"amount":1900639.471618,"amplitude":0.021196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766048400000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":33.3601,"sharesOutstanding":4920000,"nav":33.16,"aum":163147200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.12,"preClose":33.095,"latestTime":"18:32 EST","volume":30,"amount":991.93,"timestamp":1766014373725},"volumeRatio":0.404948},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":4530000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.404948,"shares":4920000,"dividePrice":0,"high":33.73,"amplitude":0.021196,"preClose":33.3601,"low":33.0229,"week52Low":25.63,"pbRate":"--","week52High":34,"institutionHeld":0,"latestPrice":33.095,"eps":0,"divideRate":0,"volume":57293,"delay":0,"ttmEps":0,"open":33.73,"prevYearClose":25.88,"prevWeekClose":33.4384,"prevMonthClose":33.5975,"prevQuarterClose":31.475,"fiveDayClose":33.5031,"twentyDayClose":32.59,"sixtyDayClose":31.9663},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1131509857","title":"Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1131509857","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131509857?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:20","pubTimestamp":1765956051,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. (referred to as \"Junshi Biosciences\") recently submitted its prospectus to the Hong Kong Stock Exchange. The company, a biotech firm focused on innovative cell...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","PFS","BK4585","BK4139","LU2487616109.SGD","ORR","BK4211","BK4505","BK4195","L","LU0053666078.USD","BK4107","LU0210528500.USD","BK4588"],"gpt_icon":0},{"id":"2591625183","title":"Why Is Immunome Stock Soaring Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625183","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625183?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:12","pubTimestamp":1765818720,"startTime":"0","endTime":"0","summary":"Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key endpoints.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/15/Portrait-Of-A-Multiethnic-Student-Workin.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49399557/why-is-immunome-stock-soaring-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ORR","IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2590043935","title":"Additional Confirmed Response Reported as Part of Amplia Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590043935","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590043935?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:45","pubTimestamp":1765547100,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Scienc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INNMF","BK4139","ORR","PR","BK4213"],"gpt_icon":0},{"id":"2590597165","title":"InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2590597165","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590597165?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:03","pubTimestamp":1765450980,"startTime":"0","endTime":"0","summary":"BEIJING, Dec.  11, 2025  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (IC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203741/0/en/InnoCare-Announces-Approval-of-the-Next-Generation-TRK-Inhibitor-Zurletrectinib-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","PFS","OS","ORR","BK4211","BK4097","BK4195","NGS"],"gpt_icon":0}],"pageSize":4,"totalPage":36,"pageCount":1,"totalSize":141,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}